Abstracts tagged "drug therapy"

Abstract Number: 642 • 2012 ACR/ARHP Annual Meeting
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Several candidate biomarkers for Systemic Lupus Erythematosus (SLE) have been reported including STAT1, ADAR, CCL2, CXCL10, and miR-146a. This study examines the effects of…
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Philip J. Mease², Juan J. Gomez-Reino³, Adebajo Adewale⁴, Jürgen Wollenhaupt⁵, ChiaChi Hu⁶ and Randall Stevens⁶, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…
Abstract Number: 2270 • 2012 ACR/ARHP Annual Meeting
The DNA Methylome of Systemic Lupus Erythematosus (SLE) From Whole Peripheral Blood Mononuclear Cells (PBMCs)
Robert Shoemaker¹, Lou H. Bookbinder², David L. Boyle³, Gary S. Firestein⁴, Jonathan E. Lim⁵ and David W. Anderson⁶, ¹Bioinformatics, NexDx, Inc., San Diego, CA, ²Molecular Biology, NexDx, Inc., San Diego, ³Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁴Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁵Research and Development, NexDx, Inc., San Diego, ⁶Research and Development, NexDx, Inc., San Diego, CA
Background/Purpose: SLE is a disease where epigenetic mechanisms play a role. Methylation of DNA at CpG loci is known to influence the suppression or activation…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1895 • 2012 ACR/ARHP Annual Meeting
Safety Competences Knowledge and Behavioural Skills of Patients Treated by Biologics in Rheumatology
Anne-Christine Rat¹, Bruno Fautrel², Elisabeth Flipon³, Laure Gossec⁴, Benoit-Damien Caritey⁵, Laurent Marguerie⁶, Henri Nataf⁷, Beatrice Pallot Prades⁸, Rose Marie Poilvert⁹, Valerie Royant¹⁰, Fathia Sadji¹¹, Christelle Sordet¹², Corinne Thevenot¹³ and Catherine Beauvais¹⁴, ¹CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ²Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ³Cochin hospital, Paris, France, ⁴Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁵Epidemiology, Université de lorraine, Nancy, France, ⁶Rheumatology department, Institut Calot, Berck, France, ⁷Mantes-la-Jolie, Mantes-la-Jolie, France, ⁸Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁹Rheumatology department, Saint Antoine Hospital, Paris, France, ¹⁰Chartres, Chartres, ¹¹Rheumatology department, Victor Jousselin Hospital, Dreux, France, ¹²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Department of Internal Medicine, Laon hospital, Laon, France, ¹⁴Rhumatologie, Saint Antoine, Paris, France
Background/Purpose: Biologics are known to entail specific risks; therefore teaching patients safety skills, appropriate behaviours in situations of risks and what decisions to take in…
Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Jessica K. Gordon¹, Morgana L. Davids², Kamini Doobay², Jamie N. Mersten¹, Cynthia Magro³, Horatio F. Wildman⁴, Stephen L. Lyman⁵, Mary K. Crow⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Dermatopathology, Weill-Cornell Medical Center, New York, NY, ⁴Dermatology, Weill-Cornell Medical Center, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].